Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
PMID:

Abstract

Tumor-infiltrating lymphocytes (TIL) have potential prognostic value in melanoma and have been considered for inclusion in the American Joint Committee on Cancer (AJCC) staging criteria. However, interobserver discordance continues to prevent the adoption of TIL into clinical practice. Computational image analysis offers a solution to this obstacle, representing a methodological approach for reproducibly counting TIL. We sought to evaluate the ability of a TIL-quantifying machine learning algorithm to predict survival in primary melanoma. Digitized hematoxylin and eosin (H&E) slides from prospectively enrolled patients in the NYU melanoma database were scored for % TIL using machine learning and manually graded by pathologists using Clark's model. We evaluated the association of % TIL with recurrence-free survival (RFS) and overall survival (OS) using Cox proportional hazards modeling and concordance indices. Discordance between algorithmic and manual TIL quantification was assessed with McNemar's test and visually by an attending dermatopathologist. In total, 453 primary melanoma patients were scored using machine learning. Automated % TIL scoring significantly differentiated survival using an estimated cutoff of 16.6% TIL (log-rank P < 0.001 for RFS; P = 0.002 for OS). % TIL was associated with significantly longer RFS (adjusted HR = 0.92 [0.84-1.00] per 10% increase in % TIL) and OS (adjusted HR = 0.90 [0.83-0.99] per 10% increase in % TIL). In comparison, a subset of the cohort (n = 240) was graded for TIL by melanoma pathologists. However, TIL did not associate with RFS between groups (P > 0.05) when categorized as brisk, nonbrisk, or absent. A standardized and automated % TIL scoring algorithm can improve the prognostic impact of TIL. Incorporation of quantitative TIL scoring into the AJCC staging criteria should be considered.

Authors

  • Margaret Chou
    Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA.
  • Irineu Illa-Bochaca
    Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA.
  • Ben Minxi
    Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
  • Farbod Darvishian
    Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
  • Paul Johannet
    Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
  • Una Moran
    Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA.
  • Richard L Shapiro
    Division of Surgical Oncology, Department of Surgery, NYU Grossman School of Medicine, New York, NY, USA.
  • Russell S Berman
    Division of Surgical Oncology, Department of Surgery, NYU Grossman School of Medicine, New York, NY, USA.
  • Iman Osman
    Departments of Dermatology, Medicine, and Urology, NYU School of Medicine, New York, New York.
  • George Jour
    Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA. George.Jour@nyulangone.org.
  • Hua Zhong
    Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.